Web Header

OCCM BASE

A Model for Lung Cancer Patients on Medicaid

The Association of Cancer Care Centers (ACCC) has created a model framework (the Model) for cancer care providers to use in improving care coordination for lung cancer patients covered by Medicaid. A three-year grant from the Bristol-Myers Squibb Foundation provided funding for development of the Model.

Guided by an interdisciplinary Advisory Committee, led by physician champion co-principal investigators, and a TechnicalExpert Panel, ACCC developed the Model in three phases:

  • Phase one-Research and beta Model development.Learn More
  • Phase two-Testing the beta Model. Learn More
  • Phase three-Data analysis and outcomes. Learn More
Read More About:

 

ACCC is pleased to make available the Model for Improving Care Coordination- designed for programs and practices of all sizes and resource levels. The Model is a tool to evaluate the current state of care coordination for lung cancer patients and for programs and practices to i dentify focus areas for improvement and actionable next steps.Beyond a framework for evaluation and setting quality improvement priorities,the Model aligns quality improvement (QI) with existing quality measures, including Commission on Cancer standards, Medicare Quality Payment Program Ql measures, ASCO QOPI standards, NCQA Patient-Centered Specialty Practice (PCSP) requirements.

The Model has 12 assessment areas,each with a high impact on optimal care coordination for lung cancer patients.The assessment areas start at the time of initial patient referral to cancer services and continues through survivorship and end of life. Each assessment area is divided into 5 levels. Level 1 attributes represent basic care and coordination; Level 5 attributes represent optimal best practice.The Model includes a crosswalk of assessment areas to quality measures.

*Note:Under the terms of the grant, programs in the following states are excluded from participation in this project: AL,GA, KY, MS, NC, TN, SC,and WV.

Our Supporters

Support provided by Bristol-Myers Squibb Foundation

Bristol Myers Squibb